Patent ID: 6376501
Filing Date: 2002-04-23
Classification: A61K,A61P,C07D

Abstract:
A method of inhibiting a type 2 helper T cell-selective immune response in a subject in need thereof, comprising administering to the subject a composition comprising a purine derivative represented by General Formula (I) whereinR2 is hydrogen or a C1-14 hydrocarbon in which â€”CH2â€” not directly bound to the purine skeleton and CH2 in â€”CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, â€”Oâ€” or â€”Sâ€”; &boxH;CH2 may be substituted by &boxH;O or &boxH;S; Câ€”H in CH2â€” not directly bound to the purine skeleton, Câ€”H in â€”CH3 not directly bound to the purine skeleton, Câ€”H in >CHâ€” not directly bound to the purine skeleton, Câ€”H in &boxH;CHâ€” not directly bound to the purine skelton and Câ€”H in &boxH;CH2 may be substituted by N, C-halogen or Câ€”CN; R6 is hydroxyl, amino or amino which is mono- or di-substituted by a C1-10 hydrocarbon group(s); R8 is hydroxyl, mercapto, C1-18 acyloxy or C1-19 hydrocarbon group-substituting oxycarbonyloxy; and R9 is a C1-14 hydrocarbon group in which â€”CH2â€” not directly bound to the purine skeleton and CH2 in â€”CH3 not directly bound to the purine skeleton may be substituted by carbonyl, sulfonyl, â€”Oâ€” or â€”Sâ€”; &boxH;CH2 may be substituted by &boxH;O or &boxH;S; Câ€”H in â€”CH2â€” not directly bound to the purine skeleton, Câ€”H in â€”CH3 not directly bound to the purine skeleton, Câ€”H in >CHâ€” not directly bound to the purine skeleton, Câ€”H in &boxH;CHâ€” not directly bound to the purine skeleton, Câ€”H in &boxH;CH2 and Câ€”H in â‰¡CH may be substituted by N, C-halogen or Câ€”CN; or its tautomer or a pharmaceutically acceptable salt of the purine derivative or the tautomer to inhibit a type 2-helper T cell-selective immune response.